Testing and Treating ALK+ Non-Small Cell Lung Cancer
Over the last decade, advances in diagnostics and treatments for lung cancer have led to the development of targeted therapies for some lung cancer subtypes. Patients with ALK+ non-small cell lung cancer (NSCLC) are appropriate candidates for such targeted therapy. This lung cancer subtype is rare (40% of NSCLCs are adenocarcinomas and only 5% of these cancers are ALK+). Biomarker testing is needed to identify patients with this subtype and to determine the most appropriate plan of care. However, this can present unique challenges for community-based providers who may only see a few ALK+ NSCLC patients each year.
With this education project ACCC aims to support community-based practices and programs in the use of precision medicine and molecular testing in caring for patients with ALK+ NSCLC. Through this initiative ACCC will provide examples of effective practices when diagnosing, testing, and treating this patient population.
About this Project
ACCC is launching this project to support community-based practices and programs in the use of precision medicine and molecular testing in caring for patients with ALK+ NSCLC.
This project will explore current barriers and issues related to testing and treating patients with ALK+ NSCLC through an environmental scan, which will be additionally informed by the insights of the project’s expert Advisory Committee.
The primary goal of this initiative is to provide examples of effective practices for utilizing appropriate molecular testing when treating patients with ALK+ NSCLC.
ACCC thanks the following individuals for providing their expertise and insight to the Testing and Treating ALK+ NSCLC project:
- Shirish Gadgeel, MD
Barbara Ann Karmanos Cancer Institute
- Pablo Gutman, MD, MBA
Department Chair, Pathology
Holy Cross Hospital and Holy Cross Germantown Hospital
Medical Director, Holy Cross Health Cancer Institute
- Mohammad Jahanzeb, MD, FACP
University of Miami
- Danna Johnson, MD
Chair, Multidisciplinary Cancer Committee
Thomas Johns Cancer Hospital on the Johnston Willis Campus
- Corey Langer, MD
Director, Thoracic Oncology
Professor of Medicine at the Hospital of the University of Pennsylvania
- Amy Jo Pixley, MSN, RN, OCN
Oncology Nurse Navigator
Penn Medicine, Lancaster General Hospital
- David R. Spigel, MD
Lung Cancer Program Director
Sarah Cannon Research Institute/Tennessee Oncology, PLLC
- Alexander Spira, MD
Co-Director US Oncology Thoracic Oncology Program
Virginia Cancer Specialists, PC
- H. Jack West, MD
Thoracic Oncology Program, Swedish Cancer Institute